Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...

The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...

The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...

European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC: Princeton, New Jersey Monday ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Bristol-Myers Squibb Company (NYSE:BMY) 45th Annual TD Cowen Health Care Conference March 4, 2025 2:30 PM ETCompany ParticipantsAdam Lenkowsky - ...

Replacing transplant and chemo with CI-based therapy and ISRT maintains survival, reduces side effects in younger patients ...

CheckMate-816 is a randomized, open-label, multi-center trial which is evaluating the efficacy of Opdivo in combination with chemotherapy versus chemotherapy alone as a neoadjuvant treatment for ...

BMS’ Opdivo is approved in more than 65 countries. Credit: Amy Lutz/Shutterstock. The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

Bristol Myers Squibb has won Food and Drug Administration priority review for its application seeking approval of the combination of its Opdivo and Yervoy cancer drugs for the early treatment of ...

Bristol Myers (BMY) Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a potential first-line treatment option for adult and ...